For example, infliximab, a chimeric anti-TNF-α antibody, significantly reduced cognitive deficits in a female AD patient and significantly reduced Aβ- and tau-pathology and memory impairment in AD mouse models, following intrathecal and intracerebroventricular administration [22–24], respectively. The gene discussed is TNF; the disease is Alzheimer disease.